US firm enters patent settlement deal with Dr Reddy's for Qsymia drug

American Pharmaceutical Company Vivus, Inc. has entered into a settlement agreement with Dr Reddy's Laboratories Limited in a patent infringement litigation related to weight management drug Qsymia (phentermine and topiramate extended-release capsules).

The litigation, which has been pending in the district court of New Jersey since 2015, was raised after Dr Reddy's subsidiaries filed the abbreviated new drug application (ANDA) for approval to launch its generic version.

The settlement agreement permits Dr Reddy's to begin selling a generic version of Qsymia on June 1, 2025, or earlier under certain conditions. In the event of a launch earlier than